EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12
05 Febrero 2016 - 3:01PM
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company
focused on the global development and commercialization of
biosimilar monoclonal antibodies (mAbs), today announced it will
participate in multiple panel discussions at the 4th Annual
Bloomberg Intelligence Healthcare Event on Friday, Feb. 12. The
panels will begin at 1:30 pm ET and focus on the evolving
strategies for biosimilars, as well as provide legal and regulatory
updates on biosimilars.
The conference will be held on Friday, Feb. 12
starting at 8:30 am ET in New York City. Additional information is
available at http://b.bloomberg.com/BIHealthCare-regsa. The link to
the live audio webcast and replay of the presentation will be
available through Bloomberg terminals at Live <go>.
About EPIRUS
BiopharmaceuticalsEPIRUS Biopharmaceuticals (Nasdaq:EPRS)
is a biopharmaceutical company focused on the global development
and commercialization of biosimilar monoclonal antibodies (mAbs).
EPIRUS’ goal is to improve global patient access to important,
cost-effective medicines. EPIRUS' current pipeline of
biosimilar product candidates includes: BOW015 (infliximab,
reference biologic Remicade®); BOW050 (adalimumab, reference
biologic Humira®); BOW070 (tocilizumab, reference biologic
Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090
(ustekinumab, reference biologic STELARA®); and BOW100 (golimumab,
reference biologic SIMPONI®)i. The reference products for these
candidates together generated approximately $29.2 billion in global
sales for 2014, according to EvaluatePharma®. EPIRUS has
established multiple partnerships to support its regulatory and
commercialization efforts in global markets. For more information
visit EPIRUS’ website at www.epirusbiopharma.com.
i Remicade is a registered trademark of Johnson and Johnson
(www.jnj.com); Humira is a registered trademark of AbbVie
(www.abbvie.com); Actemra is a registered trademark of Chugai
Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group
(www.gene.com); Stelara is owned and marketed by Centocor Ortho
Biotech Inc, a wholly owned subsidiary of Johnson and Johnson
(www.jnj.com); Simponi is marketed by Janssen Biotech Inc
(www.janssenbiotech.com); Soliris is a registered trademark of
Alexion Pharmaceuticals, Inc. (www.alxn.com)
Contact Information:
For media inquiries:
Hope Buggey, FleishmanHillard
+1-919-336-3786
hope.buggey@fleishman.com
For investor inquiries:
Marek Ciszewski, J.D., EPIRUS Biopharmaceuticals
+1-617-553-9716
mciszewski@epirusbiopharma.com
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfica de Acción Histórica
De May 2023 a May 2024
Real-Time news about EPIRUS Biopharmaceuticals Inc (CE) (OTCMarkets): 0 recent articles
Más de Artículos de Noticias